AU2006315512B2 - Administration of an mTOR inhibitor to treat patients with cancer - Google Patents

Administration of an mTOR inhibitor to treat patients with cancer Download PDF

Info

Publication number
AU2006315512B2
AU2006315512B2 AU2006315512A AU2006315512A AU2006315512B2 AU 2006315512 B2 AU2006315512 B2 AU 2006315512B2 AU 2006315512 A AU2006315512 A AU 2006315512A AU 2006315512 A AU2006315512 A AU 2006315512A AU 2006315512 B2 AU2006315512 B2 AU 2006315512B2
Authority
AU
Australia
Prior art keywords
cancer
patient
administration
consecutive days
week
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2006315512A
Other languages
English (en)
Other versions
AU2006315512A1 (en
Inventor
Camille L. Bedrosian
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ariad Pharmaceuticals Inc
Original Assignee
Ariad Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ariad Pharmaceuticals Inc filed Critical Ariad Pharmaceuticals Inc
Publication of AU2006315512A1 publication Critical patent/AU2006315512A1/en
Assigned to ARIAD PHARMACEUTICALS, INC. reassignment ARIAD PHARMACEUTICALS, INC. Request for Assignment Assignors: ARIAD GENE THERAPEUTICS, INC.
Application granted granted Critical
Publication of AU2006315512B2 publication Critical patent/AU2006315512B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AU2006315512A 2005-11-14 2006-11-14 Administration of an mTOR inhibitor to treat patients with cancer Ceased AU2006315512B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US73676305P 2005-11-14 2005-11-14
US60/736,763 2005-11-14
PCT/US2006/044146 WO2007059106A2 (en) 2005-11-14 2006-11-14 Administration of mntor inhibitor to treat patients with cancer

Publications (2)

Publication Number Publication Date
AU2006315512A1 AU2006315512A1 (en) 2007-05-24
AU2006315512B2 true AU2006315512B2 (en) 2012-11-01

Family

ID=38049229

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2006315512A Ceased AU2006315512B2 (en) 2005-11-14 2006-11-14 Administration of an mTOR inhibitor to treat patients with cancer

Country Status (9)

Country Link
US (1) US20070185150A1 (enExample)
EP (2) EP2662082A1 (enExample)
JP (2) JP5709354B2 (enExample)
CN (2) CN102579467A (enExample)
AU (1) AU2006315512B2 (enExample)
CA (1) CA2629714A1 (enExample)
EA (1) EA015922B1 (enExample)
IL (1) IL191356A0 (enExample)
WO (1) WO2007059106A2 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008016633A2 (en) * 2006-08-02 2008-02-07 Ariad Gene Therapeutics, Inc. Combination therapy
CN103330694A (zh) * 2006-11-14 2013-10-02 阿里亚德医药股份有限公司 口服制剂
US8685995B2 (en) 2008-03-21 2014-04-01 The University Of Chicago Treatment with opioid antagonists and mTOR inhibitors
US20120064143A1 (en) 2008-11-11 2012-03-15 The Board Of Regents Of The University Of Texas System Inhibition of mammalian target of rapamycin
WO2010120599A2 (en) 2009-04-16 2010-10-21 Merck Sharp & Dohme Corp. Compositions and methods for treating cancer
US8911766B2 (en) * 2009-06-26 2014-12-16 Abbott Cardiovascular Systems Inc. Drug delivery compositions including nanoshells for triggered drug release
WO2011024168A2 (en) * 2009-08-26 2011-03-03 Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd Sustained release delivery systems for the prevention and treatment of head and neck cancers
US9283211B1 (en) 2009-11-11 2016-03-15 Rapamycin Holdings, Llc Oral rapamycin preparation and use for stomatitis
US20130035336A1 (en) * 2010-04-13 2013-02-07 Novartis Ag Combination comprising a cyclin dependent kinase 4 or cyclin dependent kinase (cdk4/6) inhibitor for treating cancer
JP2012061053A (ja) 2010-09-14 2012-03-29 Yuuki Kitaoka 投薬装置、投薬装置の作動方法及び投薬方法
AR083267A1 (es) * 2010-10-04 2013-02-13 Novartis Ag Combinaciones farmaceuticas
BR112013027486A2 (pt) * 2011-04-25 2017-02-14 Novartis Ag combinação de um inibidor de fosfatidilinositol-3-cinase (pi3k) e um inibidor de mtor
BR112014013332B1 (pt) * 2011-12-02 2022-09-06 Signal Pharmaceuticals, Llc Composições farmacêuticas de 7-(6-(2-hidroxi-propan-2-il)piridin-3-il)-1-((trans)-4- metoxicicloexil)-3,4-diidropirazino [2,3-b]pirazin-2(1h)-ona, uma forma sólida dessa e métodos de seu uso
JP6381523B2 (ja) 2012-05-16 2018-08-29 ノバルティス アーゲー Ｐｉ−３キナーゼ阻害剤の投与レジメン
US9757432B2 (en) 2012-11-14 2017-09-12 Ohio State Innovation Foundation Materials and methods useful for treating glioblastorna
US20160030401A1 (en) 2013-03-13 2016-02-04 The Board Of Regents Of The University Of Texas System Use of mtor inhibitors for prevention of intestinal polyp growth and cancer
CN104721158B (zh) * 2013-12-24 2018-01-30 正大天晴药业集团股份有限公司 一种稳定的依维莫司片剂
DK3089737T3 (da) 2013-12-31 2021-12-13 Rapamycin Holdings Llc Orale rapamycin-nanopartikelpræparater og anvendelse.
US9700544B2 (en) 2013-12-31 2017-07-11 Neal K Vail Oral rapamycin nanoparticle preparations
CN106166296A (zh) * 2016-07-01 2016-11-30 江南大学 一种辅助雷帕霉素治疗多种肿瘤的药物组合物
CN107714719A (zh) * 2017-11-08 2018-02-23 上海市第妇婴保健院 雷帕霉素在制备治疗白细胞介素‑27低表达子宫内膜癌的药物中的应用
CN115135322A (zh) * 2020-02-21 2022-09-30 韩国高等科学技术学院 包含哺乳动物雷帕霉素靶蛋白信号传导抑制剂作为有效成分的用于预防或治疗癌症的药物组合物
CN114767867A (zh) * 2021-12-22 2022-07-22 中山大学孙逸仙纪念医院 一种用于治疗cdk4/6抑制剂耐药后的乳腺癌的药物组合物及其应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002080975A1 (en) * 2001-04-06 2002-10-17 Wyeth Antineoplastic combinations such as rapamycin together with gemcitabine or fluorouracil
US20050119288A1 (en) * 2003-08-18 2005-06-02 Pfizer Inc Dosing schedule for a novel anticancer agent
WO2006039414A2 (en) * 2004-09-30 2006-04-13 Ariad Gene Therapeutics, Inc. Treatment method
WO2006089312A2 (en) * 2005-02-15 2006-08-24 Wyeth Orally bioavailable cci-779 tablet formulations

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5206018A (en) 1978-11-03 1993-04-27 Ayerst, Mckenna & Harrison, Inc. Use of rapamycin in treatment of tumors
US5378696A (en) * 1990-09-19 1995-01-03 American Home Products Corporation Rapamycin esters
US5078999A (en) 1991-02-22 1992-01-07 American Home Products Corporation Method of treating systemic lupus erythematosus
US5080899A (en) 1991-02-22 1992-01-14 American Home Products Corporation Method of treating pulmonary inflammation
US5321009A (en) 1991-04-03 1994-06-14 American Home Products Corporation Method of treating diabetes
DE69209183T2 (de) 1991-06-18 1996-08-08 American Home Prod Verwendung von Rapamycin zur Behandlung von T-Zellen Lymphom/Leukämie bei Erwachsenen
IL102414A (en) 1991-07-25 1996-08-04 Univ Louisville Res Found Medicinal preparations for the treatment of ocular inflammation, containing rapamycin
US5286730A (en) 1991-09-17 1994-02-15 American Home Products Corporation Method of treating immunoinflammatory disease
US5286731A (en) 1991-09-17 1994-02-15 American Home Products Corporation Method of treating immunoinflammatory bowel disease
US5516781A (en) 1992-01-09 1996-05-14 American Home Products Corporation Method of treating restenosis with rapamycin
US5288711A (en) 1992-04-28 1994-02-22 American Home Products Corporation Method of treating hyperproliferative vascular disease
EP1181938B1 (en) 1993-04-23 2007-11-14 Wyeth Rapamycin conjugates and antibodies
CH686761A5 (de) 1993-05-27 1996-06-28 Sandoz Ag Galenische Formulierungen.
PT1033128E (pt) 1993-09-28 2008-08-08 Scherer Gmbh R P Fabrico de cápsulas de gelatina mole
US5561138A (en) 1994-12-13 1996-10-01 American Home Products Corporation Method of treating anemia
US5496832A (en) 1995-03-09 1996-03-05 American Home Products Corporation Method of treating cardiac inflammatory disease
BE1009856A5 (fr) 1995-07-14 1997-10-07 Sandoz Sa Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule.
GB9606452D0 (en) 1996-03-27 1996-06-05 Sandoz Ltd Organic compounds
US7125875B2 (en) * 1999-04-15 2006-10-24 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
GB0000482D0 (en) 2000-01-11 2000-03-01 Norton Healthcare Ltd Enteric coated pharmaceutical formulation
LT3351246T (lt) 2001-02-19 2019-07-10 Novartis Pharma Ag Rapamicino darinys, skirtas kieto naviko, susijusio su nereguliuojama angiogeneze, gydymui
ATE317850T1 (de) 2001-05-30 2006-03-15 Novartis Pharma Gmbh 2-((n-(2-amino-3-(heteroaryl- oder - aryl)propionyl)aminoacyl)amino)- alkylboronsäurederivate
KR100956195B1 (ko) 2002-02-01 2010-05-06 어리어드 파마슈티칼스, 인코포레이티드 인 함유 화합물 및 이의 용도
ES2315530T3 (es) 2002-09-17 2009-04-01 Wyeth Formulacion granulada de un ester de rapamicina cci-779.
GB0327840D0 (en) * 2003-12-01 2003-12-31 Novartis Ag Organic compounds
ES2298861T3 (es) 2004-01-08 2008-05-16 Wyeth Composicion farmaceutica que puede obtenerse mediante compresion directa para la administracion oral de cci-779.
US7405497B2 (en) 2004-04-13 2008-07-29 Electrovaya Inc. Integrated power supply system
GB0504994D0 (en) 2005-03-11 2005-04-20 Biotica Tech Ltd Novel compounds
DE102005017313A1 (de) 2005-04-14 2006-10-19 Volkswagen Ag Verfahren zur Darstellung von Informationen in einem Verkehrsmittel und Kombiinstrument für ein Kraftfahrzeug
US20070105887A1 (en) * 2005-11-04 2007-05-10 Wyeth Antineoplastic combinations of temsirolimus and sunitinib malate

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002080975A1 (en) * 2001-04-06 2002-10-17 Wyeth Antineoplastic combinations such as rapamycin together with gemcitabine or fluorouracil
US20050119288A1 (en) * 2003-08-18 2005-06-02 Pfizer Inc Dosing schedule for a novel anticancer agent
WO2006039414A2 (en) * 2004-09-30 2006-04-13 Ariad Gene Therapeutics, Inc. Treatment method
WO2006089312A2 (en) * 2005-02-15 2006-08-24 Wyeth Orally bioavailable cci-779 tablet formulations

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Dancey, JE (2005) Expert Opin. Investig. Drugs 14: 313-328 *
Hidalgo, M et al (2006) Clinical Cancer Research 12: 5755-5763 *
Mita, MM et al (2004) 2004 ASCO Annual Meeting. General Poster Session. Abstract No 3076 *

Also Published As

Publication number Publication date
JP2014012721A (ja) 2014-01-23
CN101360495B (zh) 2012-03-14
WO2007059106A3 (en) 2008-06-05
EP2662082A1 (en) 2013-11-13
EP1962839A2 (en) 2008-09-03
IL191356A0 (en) 2009-08-03
EA015922B1 (ru) 2011-12-30
AU2006315512A1 (en) 2007-05-24
JP2009515901A (ja) 2009-04-16
CN101360495A (zh) 2009-02-04
EA200801309A1 (ru) 2008-10-30
JP5709354B2 (ja) 2015-04-30
CN102579467A (zh) 2012-07-18
US20070185150A1 (en) 2007-08-09
EP1962839A4 (en) 2010-08-25
WO2007059106A2 (en) 2007-05-24
CA2629714A1 (en) 2007-05-24

Similar Documents

Publication Publication Date Title
AU2006315512B2 (en) Administration of an mTOR inhibitor to treat patients with cancer
US12059397B2 (en) Calcium lactate compositions and methods of use
US20100266590A1 (en) Combination therapy
EP3750530B1 (en) Combinations of irs/stat3 dual modulators and anti-cancer agents for treating cancer
TWI746449B (zh) 使用阿吡莫德治療癌症之方法
TW201639578A (zh) 阿吡莫德之活性代謝物及其用途
KR20130043225A (ko) 복합 항암 요법
TW200803842A (en) Antineoplastic combinations of temsirolimus and sunitinib malate
KR20130073948A (ko) 암 치료를 위한 새로운 병용 요법
US20080207644A1 (en) Therapeutic materials and methods
US20130101680A1 (en) Radiotherapy enhancer
CN112584834B (zh) 用于治疗结外nk/t细胞淋巴瘤的喹啉衍生物
US20230132982A1 (en) Use of pyrido[1,2-a]pyrimidinone compound in treating lymphoma
EP4284378A1 (en) Ptentreating cancer in patient with pten inactivating mutation
CN1901906B (zh) 治疗套细胞淋巴瘤的cci-779
HK1173387A (en) Use of a rapamycin derivative for the treatment of cancer
EP3893875A1 (en) THERAPEUTIC COMBINATIONS OF ORALLY ADMINISTERED IRINOTECAN AND A P-gp INHIBITOR FOR THE TREATMENT OF CANCER
HK1118704B (en) Radiotherapy enhancer

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE INVENTION TITLE TO READ: ADMINISTRATION OF AN MTOR INHIBITOR TO TREAT PATIENTS WITH CANCER

PC1 Assignment before grant (sect. 113)

Owner name: ARIAD PHARMACEUTICALS, INC.

Free format text: FORMER APPLICANT(S): ARIAD GENE THERAPEUTICS, INC.

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired